Cerenome (CNSY) Q4 2024 earnings summary

Executive summary

• Closed $15M underwritten equity financing in March 2024, extending cash runway into 2026 and regaining Nasdaq compliance.

• Received $2M in accelerated grant proceeds from CPRIT, strengthening funding and supporting development.

• Advanced REYOBIQ/Rheobic clinical programs with positive Phase 1 data in glioblastoma and leptomeningeal metastases, including FDA Orphan Drug Designation.

• CNSide diagnostic platform acquired, demonstrated clinical utility, and is on track for full commercial launch in 2025.

• Expanded leadership team with key hires to support clinical, regulatory, and commercial operations.

Financial highlights

• Cash and investments at year-end 2024 were $3.6M, down from $8.6M at year-end 2023.

• 2024 grant revenue was $5.8M, up from $4.9M in 2023; 2025 grant revenue expected at $6–8M, with $2M already received.

• Operating loss for 2024 was $14.7M, compared to $13.3M in 2023, mainly due to increased R&D and RESPECT-LM trial spending.

• Net loss for 2024 was $13M ($1.95/share), compared to $13.3M ($4.24/share) in 2023.

• Weighted average shares outstanding increased to 6.6M in 2024 from 3.1M in 2023.

Outlook and guidance

• Funding runway extends through key milestones into mid-2026, supported by recent equity and grant funding.

• Full commercial launch of CNSide planned for 2025, with financial guidance to be provided later as visibility improves.

• Multiple clinical trial milestones expected in 2025, including completion of RESPECT-LM and ReSPECT-GBM trial enrollments and IND approval for pediatric trial.

• Presentations scheduled at major medical conferences throughout 2025.